Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor-Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial.
Costanza PaolettiWilliam E BarlowErin F CobainMattias BergqvistRita S MehtaJulie R GralowGabriel N HortobagyiKathy S AlbainLajos PusztaiPriyanka SharmaAndrew K GodwinAlastair M ThompsonDaniel F HayesJames M RaePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
High sTK1 at BL and subsequent timepoints is associated with worse prognosis in patients with MBC starting first-line endocrine therapy (ET). Patients with low sTK1 at BL have comparable outcomes on single-agent or combination ET.